Oclacitinib and Myxoma Virus Therapy in Dogs with High Grade Soft Tissue Sarcoma
Rattachement africain : us, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Human rhabdomyosarcomas are rarely cured by surgical resection alone. This is also true for high grade soft tissue sarcomas in dogs. Dogs with spontaneous sarcoma are good models for clinical responses to new cancer therapies. Strategic combinations of immunotherapy and oncolytic virotherapy (OV) could improve treatment responses in canine and human cancer patients. To develop an appropriate combination of immunotherapy and OV for dogs with soft tissue sarcoma (STS), canine cancer cells were inoculated with myxoma viruses (MYXVs) and gene transcripts were quantified. Next, cytokine concentrations in canine cancer cells were altered to evaluate their effect on MYXV replication. These studies indicated that, as in murine and human cells, type I interferons (IFN) play an important role in limiting MYXV replication in canine cancer cells. To reduce type I IFN production during OV, oclacitinib (a JAK1 inhibitor) was administered twice daily to dogs for 14 days starting ~7 days prior to surgery. STS tumors were excised and MYXV deleted for serp2 (MYXV∆SERP2) was administered at the surgical site at two time points post-operatively to treat any remaining microscopic tumor cells. Tumor regrowth in dogs treated with OV was decreased relative to historical controls. However, regrowth was not further inhibited in patients given combination therapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Oclacitinib and Myxoma Virus Therapy in Dogs with High Grade Soft Tissue Sarcoma
- Date Crossref
- 18/07/2023
- Éditeur
- MDPI AG
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Colorado State University pays non établi dans la noticeUniversité ou école supérieure
-
Victoria Hospital pays non établi dans la noticeÉtablissement de santé
-
Victoria General Hospital pays non établi dans la noticeÉtablissement de santé
-
College of Veterinary Medicine and Biomedical Sciences Immunology and Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Central Victoria Veterinary Hospital pays non établi dans la noticeÉtablissement de santé
Colorado State University, Victoria Hospital et Victoria General Hospital, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.